WO2004078145B1 - Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis - Google Patents
Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosisInfo
- Publication number
- WO2004078145B1 WO2004078145B1 PCT/US2004/006806 US2004006806W WO2004078145B1 WO 2004078145 B1 WO2004078145 B1 WO 2004078145B1 US 2004006806 W US2004006806 W US 2004006806W WO 2004078145 B1 WO2004078145 B1 WO 2004078145B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multiple sclerosis
- simvastatin
- glatiramer acetate
- amount
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of simvastatin, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, simvastatin and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of simvastatin, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of simvastatin, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.
Claims
24. The pharmaceutical composition of claim 23, wherein each of the amount of glatiramer acetate when taken alone and the amount of simvastatin when taken alone is effective to alleviate the symptom of multiple sclerosis.
25. The pharmaceutical composition of claim 23, wherein either of the amount of glatiramer acetate when taken alone, or the amount of simvastatin when taken alone or each such amount when taken alone is not effective to alleviate the symptom of multiple sclerosis.
26. A product containing glatiramer acetate and simvastatin as a combined preparation for simultaneous, separate or sequential use in treating a form of multiple sclerosis .
27. A product containing glatiramer acetate and simvastatin as a combined preparation for simultaneous, separate or sequential use in alleviating a symptom of a form of multiple sclerosis.
28. Use of simvastatin for the manufacture of a medicament for use in alleviating a symptom of a form of multiple sclerosis in a patient who is already being treated with glatiramer acetate.
29. Use of simvastatin for the manufacture of a medicament for use in alleviating a symptom of a form of multiple sclerosis in a patient population that is being treated with glatiramer acetate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45181703P | 2003-03-04 | 2003-03-04 | |
| US60/451,817 | 2003-03-04 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2004078145A2 WO2004078145A2 (en) | 2004-09-16 |
| WO2004078145A3 WO2004078145A3 (en) | 2005-03-24 |
| WO2004078145B1 true WO2004078145B1 (en) | 2005-05-19 |
Family
ID=32962640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/006806 Ceased WO2004078145A2 (en) | 2003-03-04 | 2004-03-04 | Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2004078145A2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040013643A1 (en) * | 2000-09-19 | 2004-01-22 | Novlmmune S.A. | Methods for treatment of multiple sclerosis with statins |
-
2004
- 2004-03-04 WO PCT/US2004/006806 patent/WO2004078145A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004078145A2 (en) | 2004-09-16 |
| WO2004078145A3 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004103297A3 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| WO2007081975A3 (en) | Method of treating multiple sclerosis | |
| GB0410266D0 (en) | Treatment of apoptosis | |
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| JP2015520188A5 (en) | ||
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| WO1999040883A3 (en) | Compositions and methods for the treatment of cystic fibrosis | |
| WO2004002445A3 (en) | Novel floating dosage form | |
| JP2004537500A5 (en) | ||
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| MXPA04007183A (en) | Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes. | |
| PT1656131E (en) | Use of betaine for treating intermittent claudication | |
| JP2006508994A5 (en) | ||
| ATE114471T1 (en) | METHODS OF TREATMENT AND PREVENTION OF BONE MASS LOSS. | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
| Brignola et al. | Influence of steroid treatment's duration in patients with active Crohn's disease | |
| WO2004078145B1 (en) | Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| RU2007112409A (en) | SIMULTANEOUS RECEPTION OF TIGICYCLINE AND DIGOXIN | |
| IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
| IL170519A (en) | Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them | |
| JP2006508993A5 (en) | ||
| LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| TW200501958A (en) | A therapeutic agent for treating a behavioral disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| B | Later publication of amended claims |
Effective date: 20050211 |
|
| 122 | Ep: pct application non-entry in european phase |